A Phase 2 interventional study of Guselkumab and Ustekinumab in Psoriatic Arthritis, sponsored by Janssen Research & Development, LLC. Completed at 41 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-04.
Sponsored by Janssen Research & Development, LLC · Phase 2, Interventional, and Treatment
The purpose of this study is to evaluate the efficacy, safety and tolerability of guselkumab in participants with Active Psoriatic Arthritis (PsA).
This is a multi-center (more than one clinical site will work on a medical research study), randomized (study medication assigned to participants by chance), double-blind (neither investigator nor participant knows which treatment the participant receives), placebo-controlled (placebo is an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial) study to determine the efficacy and safety of guselkumab in participants with PsA. The study will consist of 4 parts: Screening period (6 weeks), a double-blind treatment period (consists of guselkumab and placebo treatment for 24 weeks), an active treatment period (guselkumab for 20 weeks), and follow-up period (12 weeks). The maximal study duration for a participant will not exceed 62 weeks including the Screening period. Eligible participants will be randomly assigned to one of two groups in a 2:1 ratio to either receive Guselkumab 100 milligram (mg) at Weeks 0, 4 then every 8 weeks or Placebo at Weeks 0, 4 then every 8 weeks until Week 24. At week 24, participants remaining in the placebo group will start to receive guselkumab 100 mg at Weeks 24, 28, 36 and 44. Participants in both treatment groups who have less than (\<) 5 percent (%) improvement from baseline in both tender and swollen joint counts at Week 16 will qualify for early escape and will switch to open-label therapy with ustekinumab 45 mg or 90 mg at Weeks 16, 20, 32, and 44 based on the approved dosage for the PsA indication in the particular country of study. The efficacy will be assessed primarily by measuring percentage of participants who achieve an American College of Rheumatology (ACR) 20 Response at Week 24. Participants' safety will be monitored throughout the study.
3,554 studies on the registry are indexed under Arthritis; 317 are open to participants now.
This study's enrollment of 149 is above the median of 90 across 2,377 interventional studies indexed under Arthritis.
Browse Arthritis studies →Janssen Research & Development, LLC is the lead sponsor of 912 studies on the registry; 76 are open to participants now.
Of its 278 completed or terminated interventional studies of FDA-regulated products, 131 (47%) have results posted.
Counted across the registry records on this site, refreshed daily.
Had active PsA as defined by:
Exclusion Criteria:
Participants will receive guselkumab 100 milligram (mg) subcutaneous injection (injected under the skin by way of a needle) at Weeks 0, 4, 12, 20, 28, 36, and 44, and placebo for guselkumab at Week 24 to maintain the blind. Participants who enter early escape at Week 16 will switch to open label therapy with ustekinumab 45 mg or 90 mg at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.
Drug: Guselkumab · Drug: Ustekinumab · Drug: Placebo
Participants will receive placebo for guselkumab at Weeks 0, 4, 12, and 20, and guselkumab 100 mg subcutaneous injection at Weeks 24, 28, 36, and 44. Participants who enter early escape at Week 16 will switch to open label therapy with ustekinumab 45 mg or 90 mg at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.
Drug: Guselkumab · Drug: Ustekinumab · Drug: Placebo
In the guselkumab group, Guselkumab 100 mg subcutaneous injection will be administered at Weeks 0, 4, 12, 20, 28, 36 and 44. In the placebo group, guselkumab 100 mg subcutaneous injection will be administered at Weeks 24, 28, 36 and 44 for participants remaining on placebo at Week 24.
In both placebo and guselkumab groups, if the participants qualify for early escape, they will switch to receive ustekinumab 45 mg or 90 mg subcutaneous injection at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.
In placebo group, Placebo subcutaneous injection will be administered at Weeks 0, 4, 12, and 20. In guselkumab group, placebo subcutaneous injection will be administered at Week 24 to maintain the blind.
Percentage of Participants Who Achieved American College of Rheumatology (ACR) 20 Response at Week 24
ACR 20 response: at least 20% improvement from baseline in both swollen joint (66 joints) and tender joint (68 joints) counts and at least 20% improvement from baseline in 3 of following 5 assessments: patient's assessment of pain (VAS: 0-100 millimeter \[mm\], 0=no pain and 100=worst possible pain), patient's global assessment of disease activity on arthritis (VAS:0-100mm, 0=excellent and 100=poor), physician's global assessment of disease activity (VAS:0-100mm; 0=no arthritis activity and 100 = extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas;derived HAQ-DI ranges from 0=no difficulty, to 3=inability to perform a task in that area) and serum CRP. Treatment Failure (TF) criteria: Discontinued study drug due to lack of efficacy or worsening of PsA, initiated or increased dose of methotrexate or oral corticosteroids, or initiated prohibited PsA treatments. FAS is full analysis set.
Time frame: Week 24
Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI)-75 Response at Week 24
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72 (worst condition). PASI 75 response was defined as at least a 75% reduction in PASI relative to Baseline. As planned, results data was analyzed and reported for the specified arms for this outcome measure.
Time frame: Week 24
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24
Change from baseline in HAQ-DI score is a measure of the change in the physical function, where a negative change reflects an improvement and a positive change reflects worsening of physical function. HAQ-DI is a 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0 indicating no difficulty, to 3 indicating inability to perform a task in that area (that is, lower scores are indicative of better functioning). The total HAQ-DI score ranges from 0-24 with lower score indicating better functioning.
Time frame: Baseline and Week 24
Percentage of Participants Who Achieved an ACR 20 Response at Week 16
ACR 20 response is defined as at least 20 percent (%) improvement from baseline in both swollen joint (66 joints) and tender joint (68 joints) counts and at least 20% improvement from baseline in 3 of following 5 assessments: patient's assessment of pain (visual analog scale \[VAS\]: 0-100 millimeter \[mm\]; 0=no pain and 100=worst possible pain), patient's global assessment of disease activity on arthritis (VAS: 0-100 mm, 0=excellent and 100=poor), physician's global assessment of disease activity (VAS: 0-100mm; 0=no arthritis activity and 100 = extremely active arthritis), patient's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas;derived HAQ-DI ranges from 0 indicating no difficulty, to 3 indicating inability to perform a task in that area) and serum C-Reactive Protein (CRP).
Time frame: Week 16
Percentage of Participants Who an Achieved ACR 50 Response at Week 24
ACR 50 response is defined as at least 50 % improvement from baseline in both swollen joint (66 joints) and tender joint (68 joints) counts and at least 50% improvement from baseline in 3 of following 5 assessments: patient's assessment of pain (VAS:0-100 mm; 0=no pain and 100=worst possible pain), patient's global assessment of disease activity on arthritis (VAS:0-100mm; 0=excellent and 100=poor), physician's global assessment of disease activity (VAS: 0-100mm; 0=no arthritis activity and 100 = extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas;derived HAQ-DI ranges from 0 indicating no difficulty, to 3 indicating inability to perform a task in that area) and serum CRP.
Time frame: Week 24
Percent Change From Baseline in Leeds Enthesitis Index (LEI) Scores Among Participants With Enthesitis at Week 24
Enthesitis was assessed using the Leeds Enthesitis Index (LEI). The LEI was developed to assess enthesitis in participants with psoriatic arthritis (PsA), and evaluates the presence (score of 1) or absence of pain (score of 0) by applying local pressure to Lateral elbow epicondyle, left and right, Medial femoral condyle, left and right, and Achilles tendon insertion, left and right. LEI scores ranging from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness).
Time frame: Baseline and Week 24
Percent Change From Baseline in Dactylitis Scores Among Participants With Dactylitis at Baseline at Week 24
Dactylitis is characterized by swelling of the entire finger or toe. The severity of dactylitis is scored on a scale of 0-3, where 0, 1, 2, 3 indicates none, mild, moderate, severe, respectively in each digit of the hands and feet. The range of total dactylitis scores for a participant is 0-60. Higher score indicates more severe dactylitis.
Time frame: Baseline and Week 24
Percentage of Participants Who Achieved ACR 20, ACR 50, and ACR 70 Responses at Weeks 4, 8, 12, 16, 20, and 24
ACR 20, 50, and 70 response is defined as at least 20%, 50%, and 70% improvement from baseline in swollen joint (66 joints) and tender joint (68 joints) counts and at least 20%, 50%, and 70% improvement from baseline in 3 of following 5 assessments: patient's assessment of pain (VAS: 0-100mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity on arthritis (VAS: 0-100mm; 0=excellent and 100=poor), physician's global assessment of disease activity (VAS: 0-100mm; 0=no arthritis activity and 100= extremely active arthritis), patient's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas;derived HAQ-DI ranges from 0 indicating no difficulty, to 3 indicating inability to perform a task in that area) and serum C-Reactive Protein (CRP).
Time frame: Weeks 4, 8, 12, 16, 20, and 24
Percentage of Participants Who Achieved ACR 20, ACR 50, and ACR 70 Responses at Weeks 24, 28, 32, 36, 44, and 56
ACR 20, ACR 50 and ACR 70 response is defined as at least 20%, 50%, and 70% improvement from baseline in swollen joint (66 joints) and tender joint (68 joints) counts and at least 20%, 50%, and 70% improvement from baseline in 3 of following 5 assessments: patient's assessment of pain (VAS: 0-100mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity on arthritis (VAS: 0-100mm; 0=excellent and 100=poor), physician's global assessment of disease activity (VAS; 0-100mm; 0=no arthritis activity and 100 = extremely active arthritis), patient's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas;derived HAQ-DI ranges from 0 indicating no difficulty, to 3 indicating inability to perform a task in that area) and serum C-Reactive Protein (CRP). As planned, results data was analyzed and reported for the specified arms for this outcome measure.
Time frame: Weeks 24, 28, 32, 36, 44, and 56
Percent Change From Baseline in the ACR Components at Weeks 12 and 24
The 7 components of ACR response are: swollen joint counts (0-66), tender joint counts (0-68), patient's assessment of pain (PAIN) (VAS:0-100mm; 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (GDPT) on arthritis (VAS:0-100mm; 0=excellent and 100= poor), physician's global assessment of disease activity (GDEV) (VAS: 0-100mm; 0=no arthritis activity and 100 = extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (20-question instrument assessing 8 functional areas (total score of 0-24 with lower score indicating better functioning);derived HAQ-DI ranges from 0 indicating no difficulty, to 3 indicating inability to perform a task in that area) and serum CRP.
Time frame: Baseline and Weeks 12, 24
Percent Change From Baseline in the ACR Components at Weeks 24, 28, 32, 36, 44 and 56
The 7 components of ACR response are: swollen joint counts (0-66), tender joint counts (0-68), patient's assessment of pain (PAIN) (VAS:0-100mm; 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (GDPT) on arthritis (VAS:0-100mm; 0=excellent and 100= poor), physician's global assessment of disease activity (GDEV) (VAS: 0-100mm; 0=no arthritis activity and 100 = extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (20-question instrument assessing 8 functional areas (total score of 0-24 with lower score indicating better functioning);derived HAQ-DI ranges from 0 indicating no difficulty, to 3 indicating inability to perform a task in that area) and serum CRP.
Time frame: Basline and Weeks 24, 28, 32, 36, 44, 56
Change From Baseline in HAQ-DI Response at Weeks 4, 8, 12, 16, 20, and 24
Change from baseline in HAQ-DI score is a measure of the change in the physical function, where a negative change reflects an improvement and a positive change reflects worsening of physical function. HAQ-DI is a 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0 indicating no difficulty, to 3 indicating inability to perform a task in that area (that is, lower scores are indicative of better functioning). The total HAQ-DI score ranges from 0-24 with lower score indicating better functioning.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20, 24
Change From Baseline in HAQ-DI Score at Weeks 24, 28, 32, 36, 44, and 56
Change from baseline in HAQ-DI score is a measure of the change in the physical function, where a negative change reflects an improvement and a positive change reflects worsening of physical function. HAQ-DI is a 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area (that is, lower scores are indicative of better functioning). The total HAQ-DI score ranges from 0-24 with lower score indicating better functioning.
Time frame: Baseline and Weeks 24, 28, 32, 36, 44, 56
Percentage of Participants Who Achieved a HAQ-DI Response With Greater Than or Equal to (>=) 0.3 Improvement From Baseline in HAQ-DI Score at Weeks 4, 8, 12, 16, 20, and 24
HAQ-DI response was defined as \>= 0.3 improvement from baseline in HAQ-DI score. HAQ-DI is a 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0 indicating no difficulty, to 3 indicating inability to perform a task in that area (that is, lower scores are indicative of better functioning). The total HAQ-DI score ranges from 0-24 with lower score indicating better functioning.
Time frame: Weeks 4, 8, 12, 16, 20, and 24
Percentage of Participants Who Achieved an HAQ-DI Response With >= -0.3 Improvement From Baseline in HAQ-DI Score at Weeks 24, 28, 32, 36, 44, and 56
HAQ-DI response was defined as \>= 0.3 improvement from baseline in HAQ-DI score. HAQ-DI is a 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0 indicating no difficulty, to 3 indicating inability to perform a task in that area (that is, lower scores are indicative of better functioning). The total HAQ-DI score ranges from 0-24 with lower score indicating better functioning. As planned, results data was analyzed and reported for the specified arms for this outcome measure.
Time frame: Weeks 24, 28, 32, 36, 44, 56
Percent Change From Baseline in Dactylitis Scores at Weeks 4, 8, 16, and 24
Dactylitis is characterized by swelling of the entire finger or toe. The severity of dactylitis is scored on a scale of 0-3, where 0, 1, 2, 3 indicates none, mild, moderate, severe, respectively in each digit of the hands and feet. The range of total dactylitis scores for a participant is 0-60. Higher score indicates more severe dactylitis.
Time frame: Baseline and Weeks 4, 8, 16, 24
Percent Change From Baseline in Dactylitis Scores at Weeks 24, 28, 32, 44, 56
Dactylitis was characterized by swelling of the entire finger or toe. The severity of dactylitis is scored on a scale of 0-3, where 0, 1, 2, 3 indicates none, mild, moderate, severe, respectively in each digit of the hands and feet. The range of total dactylitis scores for a participant is 0-60. Higher score indicates more severe dactylitis. As planned, results data was analyzed and reported for the specified arms for this outcome measure.
Time frame: Baseline and Weeks 24, 28, 32, 44, 56
Percentage of Participants With Dactylitis at Weeks 4, 8, 16, and 24
Dactylitis is characterized by swelling of the entire finger or toe. The severity of dactylitis is scored on a scale of 0-3, where 0, 1, 2, 3 indicates none, mild, moderate, severe, respectively in each digit of the hands and feet. The range of total dactylitis scores for a participant is 0-60. Participants with dactylitis had dactylitis score \>0. Higher score indicates more severe dactylitis.
Time frame: Weeks 4, 8, 16, and 24
Percentage of Participants With Dactylitis at Weeks 24, 28, 32, 44, and 56
Dactylitis was characterized by swelling of the entire finger or toe. The severity of dactylitis is scored on a scale of 0-3, where 0, 1, 2, 3 indicates none, mild, moderate, severe, respectively in each digit of the hands and feet. The range of total dactylitis scores for a participant is 0-60. Higher score indicates greater degree of tenderness.
Time frame: Weeks 24, 28, 32, 44, and 56
Percent Change From Baseline in LEI Scores at Week 4, 8, 16, and 24
Enthesitis was assessed using the Leeds Enthesitis Index (LEI). The LEI was developed to assess enthesitis in participants with psoriatic arthritis (PsA), and evaluates the presence (score of 1) or absence of pain (score of 0) by applying local pressure to Lateral elbow epicondyle, left and right, Medial femoral condyle, left and right, and Achilles tendon insertion, left and right. LEI scores ranging from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness).
Time frame: Baseline and Weeks 4, 8, 16, 24
Percent Change From Baseline in LEI Scores at Weeks 24, 28, 32, 44, and 56
Enthesitis will be assessed using the Leeds Enthesitis Index (LEI). The LEI was developed to assess enthesitis in participants with PsA, and evaluates the presence (score of 1) or absence of pain (score of 0) by applying local pressure to Lateral elbow epicondyle, left and right, Medial femoral condyle, left and right, and Achilles tendon insertion, left and right. LEI scores ranging from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness).
Time frame: Baseline and Weeks 24, 28, 32, 44, 56
Percentage of Participants With Enthesitis Based on LEI Score at Weeks 4, 8, 16, and 24 in Participants With Enthesitis at Baseline
Enthesitis was assessed using the Leeds Enthesitis Index (LEI). The LEI was developed to assess enthesitis in participants with PsA, and evaluates the presence (score of 1) or absence of pain (score of 0) by applying local pressure to Lateral elbow epicondyle, left and right, Medial femoral condyle, left and right, and Achilles tendon insertion, left and right. Participants with enthesitis had LEI score \>0. LEI scores ranging from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness).
Time frame: Weeks 4, 8, 16, and 24
Percentage of Participants With Enthesitis Based on LEI at Weeks 24, 28, 32, 44, and 56 in Participants With Enthesitis at Baseline
Enthesitis will be assessed using the Leeds Enthesitis Index (LEI). The LEI was developed to assess enthesitis in participants with PsA, and evaluates the presence (score of 1) or absence of pain (score of 0) by applying local pressure to Lateral elbow epicondyle, left and right, Medial femoral condyle, left and right, and Achilles tendon insertion, left and right. Participants with enthesitis had LEI score \>0. LEI scores ranging from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness).
Time frame: Weeks 24, 28, 32, 44, and 56
Change From Baseline in Psoriatic ArthritiS Disease Activity Score (PASDAS) Score at Weeks 16 and 24
Change from baseline in PASDAS score measures the change in disease activity where a negative value indicates an improvement and a positive value indicates worsening of PsA disease activity. PASDAS is a PsA disease activity score that assesses 4 domains (joints, entheses, dactylitis and quality of life) of PsA. PASDAS is a derived score combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, on a 100-unit VAS), Physician's Global Assessment of Disease Activity (on a 100-unit VAS), swollen joint count (66 joints), tender joint count (68 joints), CRP (mg/L), enthesitis based on LEI (scaled to a 0-6 range), dactylitis count (scoring each digit from 0-3 and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score of the SF-36 health survey. The total score range is 0-10 and the cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.
Time frame: Baseline and Weeks 16, 24
Change From Baseline in PASDAS Score at Weeks 24 and 44
Change from baseline in PASDAS score measures the change in disease activity where a negative value indicates an improvement and a positive value indicates worsening of PsA disease activity. PASDAS is a PsA disease activity score that assesses 4 domains (joints, entheses, dactylitis and quality of life) of PsA. PASDAS is a derived score combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, on a 100-unit VAS), Physician's Global Assessment of Disease Activity (on a 100-unit VAS), swollen joint count (66 joints), tender joint count (68 joints), CRP (mg/L), enthesitis based on LEI (scaled to a 0-6 range), dactylitis count (scoring each digit from 0-3 and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score of the SF-36 health survey. The total score range is 0-10 and the cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.
Time frame: Baseline and Weeks 24, 44
Change From Baseline in GRAppa Composite scorE (GRACE) Index Score at Weeks 16 and 24
Change from baseline in GRACE index score measures the change in disease activity, where a negative change indicates an improvement and a positive change indicates a worsening of PsA disease activity. GRACE index was converted from Arithmetic Mean of the Desirability Function (AMDF). AMDF is calculated by transforming all variables using predefined algorithms and expressing the total score as a mean with a score range of 0 - 1, where 1 indicates a better state than 0. GRACE Index = (1 - AMDF)\*10, where GRACE index has a range of 0-10, with higher scores indicate more active disease. As planned, results data was analyzed and reported for the specified arms for this outcome measure.
Time frame: Baseline and Weeks 16, 24
Change From Baseline in GRACE Index Score at Weeks 24 and 44
Change from baseline in GRACE index score measures the change in disease activity, where a negative change indicates an improvement and a positive change indicates a worsening of PsA disease activity. GRACE index was converted from Arithmetic Mean of the Desirability Function (AMDF). AMDF is calculated by transforming all variables using predefined algorithms and expressing the total score as a mean with a score range of 0 - 1, where 1 indicates a better state than 0. GRACE Index = (1 - AMDF)\*10, where GRACE index has a range of 0-10, with higher scores indicate more active disease.
Time frame: Baseline and Weeks 24, 44
Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score at Weeks 16 and 24
The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity.
Time frame: Baseline and Weeks 16, 24
Change From Baseline in mCPDAI Index Score at Weeks 24 and 44
The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity.
Time frame: Baseline and Weeks 24, 44
Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) Score at Weeks 4, 8, 12, 16, 20 and 24
Change from baseline in DAPSA measures the change in disease activity, where a negative change indicates an improvement and a positive change indicates worsening of disease activity. DAPSA score is a the sum of swollen joint count (66 joints), tender joint count (68 joints), CRP (mg/dL), Patient's Assessment of Pain (on a 10-unit VAS;0=no pain, 10=worst possible pain), and Patient's Global Assessment of Disease Activity (arthritis, on a 10-unit VAS; 0 to 100 centimeter \[cm\] VAS, 0=excellent and 10=poor). Cut-off values for disease activity: 0-4 remission; 5-14 low; 15-28 moderate; \>28 high.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20, 24
Change From Baseline in DAPSA Index Score at Weeks 24, 28, 32, 36, 44, and 56
Change from baseline in DAPSA measures the change in disease activity, where a negative change indicates an improvement and a positive change indicates worsening of disease activity. DAPSA score is a the sum of swollen joint count (66 joints), tender joint count (68 joints), CRP (mg/dL), Patient's Assessment of Pain (on a 10-unit VAS;0=no pain, 10=worst possible pain), and Patient's Global Assessment of Disease Activity (arthritis, on a 10-unit VAS; 0 to 10cm VAS, 0=excellent and 10=poor). Cut-off values for disease activity: 0-4 remission; 5-14 low; 15-28 moderate; \>28 high.
Time frame: Baseline and Weeks 24, 28, 32, 36, 44, 56
Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 16 and 24
MDA defines a satisfactory state of disease activity that includes 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity on arthritis and psoriasis, physical function and enthesitis). Participants were classified as achieving MDA if they fulfilled 5 of 7 outcome measures: tender joint count \<=1; swollen joint count \<=1; PASI \<=1; patient pain VAS score of \<=15 mm; patient global disease activity on arthritis and psoriasis; VAS score of \<=20 mm; Health Assessment Questionnaire score \<=0.5; and tender entheseal points \<=1.
Time frame: Weeks 16 and 24
Percentage of Participants Who Achieved MDA at Weeks 24 and 44
MDA defines a satisfactory state of disease activity that includes 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity on arthritis and psoriasis, physical function and enthesitis). Participants were classified as achieving MDA if they fulfilled 5 of 7 outcome measures: tender joint count \<=1; swollen joint count \<=1; PASI \<=1; patient pain VAS score of \<=15 mm; patient global disease activity on arthritis and psoriasis; VAS score of \<=20 mm; Health Assessment Questionnaire score \<=0.5; and tender entheseal points \<=1.
Time frame: Weeks 24 and 44
Change From Baseline in the Physical and Mental Component Summary (PCS and MCS) Scores of 36- Item Short Form Health Assessment Questionnaire (SF-36) at Weeks 16 and 24
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS and MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms as presented in this outcome measure. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Time frame: Baseline and Weeks 16, 24
Change From Baseline in the PCS Scores of SF-36 at Weeks 24 and 44
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms as presented in this outcome measure. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Time frame: Baseline and Weeks 24, 44
Change From Baseline in the MCS Scores of SF-36 at Weeks 24 and 44
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms as presented in this outcome measure. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Time frame: Baseline and Weeks 24, 44
Change From Baseline in Norm-based SF-36 Scales at Week 16 and 24
SF-36 evaluates 8 individual subscales (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health). Each 8 scales scored from 0 to 100 with higher scores= better health. The scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher scores indicate better health. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Time frame: Baseline and Weeks 16, 24
Change From Baseline in Norm-based SF-36 Scale at Week 24 and 44
SF-36 evaluates 8 individual subscales (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health). Each 8 scales scored from 0 to 100 with higher scores= better health. The scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher scores indicate better health. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Time frame: Baseline and Weeks 24, 44
Change From Baseline in Routine Assessment of Patient Index Data 3 (RAPID3) Score at Weeks 16 and 24
RAPID3 is a multi-dimensional health assessment questionnaire that was designed for use in routine clinical care. Three core data set for function, pain, and patient global estimate of disease activity were recorded. Each was scored 0-10 and the score ranges from 0 to 30 with higher scores indicating worse condition. A negative change from baseline indicates improvement in condition.
Time frame: Baseline and Weeks 16, 24
Change From Baseline in RAPID3 Score at Weeks 24 and 44
RAPID3 is a multi-dimensional health assessment questionnaire that was designed for use in routine clinical care. Three core data set for function, pain, and patient global estimate of disease activity were recorded. Each was scored 0-10 and the score ranges from 0 to 30 with higher scores indicating worse condition. A negative change from baseline indicates improvement in condition.
Time frame: Baseline and Weeks 24, 44
Percentage of Participants Who Achieved a PASI 50, PASI 75, PASI 90 and PASI 100 Response at Weeks 16 and 24
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. PASI 50, 75, 90, and 100 responses were defined as at least a 50%, 75%, 90%, and 100% reduction in PASI relative to Baseline respectively. As planned, results data was analyzed and reported for the specified arms for this outcome measure.
Time frame: Weeks 16 and 24
Percentage of Participants Who Achieved a PASI 50, PASI 75, PASI 90 and PASI 100 Response at Weeks 24, 28, 32, 44, and 56
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. PASI 50, 75, 90, and 100 responses were defined as at least a 50%, 75%, 90%, and 100% reduction in PASI relative to Baseline respectively.
Time frame: Weeks 24, 28, 32, 44, and 56
Percent Change From Baseline in PASI Score at Weeks 4, 8, 16, and 24
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A negative percent change from baseline indicates the percent improvement from baseline in the severity of psoriatic lesions. As planned, results data was analyzed and reported for the specified arms for this outcome measure.
Time frame: Baseline and Weeks 4, 8, 16, 24
Percent Change From Baseline in PASI Score at Weeks 24, 28, 32, 44, and 56
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A negative percent change from baseline indicates the percent improvement from baseline in the severity of psoriatic lesions.
Time frame: Baseline and Weeks 24, 28, 32, 44, 56
| Milestone | Placebo (Week 0 to Week 24) | Placebo to Guselkumab (Week 24 to Week 56) | Guselkumab (Week 0 to Week 56) | Placebo to Ustekinumab (Week 16 to Week 56) | Guselkumab to Ustekinumab (Week 16 to Week 56) |
|---|---|---|---|---|---|
| Started | 49 | 0 | 100 | 0 | 0 |
| Completed | 48 | 0 | 99 | 0 | 0 |
| Not completed | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Not met all inclusion criteria | 0 | 0 | 1 | 0 | 0 |
| Milestone | Placebo (Week 0 to Week 24) | Placebo to Guselkumab (Week 24 to Week 56) | Guselkumab (Week 0 to Week 56) | Placebo to Ustekinumab (Week 16 to Week 56) | Guselkumab to Ustekinumab (Week 16 to Week 56) |
|---|---|---|---|---|---|
| Started | 31 | 0 | 89 | 17 | 10 |
| Completed | 29 | 0 | 86 | 17 | 10 |
| Not completed | 2 | 0 | 3 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 | 0 | 0 |
| Milestone | Placebo (Week 0 to Week 24) | Placebo to Guselkumab (Week 24 to Week 56) | Guselkumab (Week 0 to Week 56) | Placebo to Ustekinumab (Week 16 to Week 56) | Guselkumab to Ustekinumab (Week 16 to Week 56) |
|---|---|---|---|---|---|
| Started | 0 | 29 | 86 | 17 | 10 |
| Completed | 0 | 28 | 84 | 15 | 8 |
| Not completed | 0 | 1 | 2 | 2 | 2 |
| Withdrew: Adverse event | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 2 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 |
ACR 20 response: at least 20% improvement from baseline in both swollen joint (66 joints) and tender joint (68 joints) counts and at least 20% improvement from baseline in 3 of following 5 assessments: patient's assessment of pain (VAS: 0-100 millimeter \[mm\], 0=no pain and 100=worst possible pain), patient's global assessment of disease activity on arthritis (VAS:0-100mm, 0=excellent and 100=poor), physician's global assessment of disease activity (VAS:0-100mm; 0=no arthritis activity and 100 = extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas;derived HAQ-DI ranges from 0=no difficulty, to 3=inability to perform a task in that area) and serum CRP. Treatment Failure (TF) criteria: Discontinued study drug due to lack of efficacy or worsening of PsA, initiated or increased dose of methotrexate or oral corticosteroids, or initiated prohibited PsA treatments. FAS is full analysis set.
| percentage of participants | Placebo | Guselkumab |
|---|---|---|
| Percentage of Participants Who Achieved American College of Rheumatology (ACR) 20 Response at Week 24 | 18.4 | 58.0 |
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72 (worst condition). PASI 75 response was defined as at least a 75% reduction in PASI relative to Baseline. As planned, results data was analyzed and reported for the specified arms for this outcome measure.
| percentage of participants | Placebo | Guselkumab |
|---|---|---|
| Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI)-75 Response at Week 24 | 12.5 | 78.6 |
Change from baseline in HAQ-DI score is a measure of the change in the physical function, where a negative change reflects an improvement and a positive change reflects worsening of physical function. HAQ-DI is a 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0 indicating no difficulty, to 3 indicating inability to perform a task in that area (that is, lower scores are indicative of better functioning). The total HAQ-DI score ranges from 0-24 with lower score indicating better functioning.
| units on a scale | Placebo | Guselkumab |
|---|---|---|
| Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24 | -0.06 ± 0.530 | -0.42 ± 0.512 |
ACR 20 response is defined as at least 20 percent (%) improvement from baseline in both swollen joint (66 joints) and tender joint (68 joints) counts and at least 20% improvement from baseline in 3 of following 5 assessments: patient's assessment of pain (visual analog scale \[VAS\]: 0-100 millimeter \[mm\]; 0=no pain and 100=worst possible pain), patient's global assessment of disease activity on arthritis (VAS: 0-100 mm, 0=excellent and 100=poor), physician's global assessment of disease activity (VAS: 0-100mm; 0=no arthritis activity and 100 = extremely active arthritis), patient's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas;derived HAQ-DI ranges from 0 indicating no difficulty, to 3 indicating inability to perform a task in that area) and serum C-Reactive Protein (CRP).
| percentage of participants | Placebo | Guselkumab |
|---|---|---|
| Percentage of Participants Who Achieved an ACR 20 Response at Week 16 | 16.3 | 60.0 |
ACR 50 response is defined as at least 50 % improvement from baseline in both swollen joint (66 joints) and tender joint (68 joints) counts and at least 50% improvement from baseline in 3 of following 5 assessments: patient's assessment of pain (VAS:0-100 mm; 0=no pain and 100=worst possible pain), patient's global assessment of disease activity on arthritis (VAS:0-100mm; 0=excellent and 100=poor), physician's global assessment of disease activity (VAS: 0-100mm; 0=no arthritis activity and 100 = extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas;derived HAQ-DI ranges from 0 indicating no difficulty, to 3 indicating inability to perform a task in that area) and serum CRP.
| percentage of participants | Placebo | Guselkumab |
|---|---|---|
| Percentage of Participants Who an Achieved ACR 50 Response at Week 24 | 10.2 | 34.0 |
Enthesitis was assessed using the Leeds Enthesitis Index (LEI). The LEI was developed to assess enthesitis in participants with psoriatic arthritis (PsA), and evaluates the presence (score of 1) or absence of pain (score of 0) by applying local pressure to Lateral elbow epicondyle, left and right, Medial femoral condyle, left and right, and Achilles tendon insertion, left and right. LEI scores ranging from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness).
| percent change | Placebo | Guselkumab |
|---|---|---|
| Percent Change From Baseline in Leeds Enthesitis Index (LEI) Scores Among Participants With Enthesitis at Week 24 | -33.33 (-100.0 to 0.0) | -100.00 (-100.0 to -10.0) |
Dactylitis is characterized by swelling of the entire finger or toe. The severity of dactylitis is scored on a scale of 0-3, where 0, 1, 2, 3 indicates none, mild, moderate, severe, respectively in each digit of the hands and feet. The range of total dactylitis scores for a participant is 0-60. Higher score indicates more severe dactylitis.
| percent change | Placebo | Guselkumab |
|---|---|---|
| Percent Change From Baseline in Dactylitis Scores Among Participants With Dactylitis at Baseline at Week 24 | -33.33 (-66.7 to 0.0) | -100.00 (-100.0 to -50.0) |
ACR 20, 50, and 70 response is defined as at least 20%, 50%, and 70% improvement from baseline in swollen joint (66 joints) and tender joint (68 joints) counts and at least 20%, 50%, and 70% improvement from baseline in 3 of following 5 assessments: patient's assessment of pain (VAS: 0-100mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity on arthritis (VAS: 0-100mm; 0=excellent and 100=poor), physician's global assessment of disease activity (VAS: 0-100mm; 0=no arthritis activity and 100= extremely active arthritis), patient's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas;derived HAQ-DI ranges from 0 indicating no difficulty, to 3 indicating inability to perform a task in that area) and serum C-Reactive Protein (CRP).
| percentage of participants | Placebo | Guselkumab |
|---|---|---|
| Week 4: ACR 20 responders | 0 | 21.0 |
| Week 4: ACR 50 responders | 0 | 1.0 |
| Week 4: ACR 70 responders | 0 | 0 |
| Week 8: ACR 20 responders | 22.4 | 42.0 |
| Week 8: ACR 50 responders | 6.1 | 12.0 |
| Week 8: ACR 70 responders | 2.0 | 4.0 |
| Week 12: ACR 20 responders | 12.2 | 49.0 |
| Week 12: ACR 50 responders | 6.1 | 15.0 |
| Week 12: ACR 70 responders | 0 | 7.0 |
| Week 16: ACR 20 responders | 16.3 | 60.0 |
| Week 16: ACR 50 responders | 6.1 | 30.0 |
| Week 16: ACR 70 responders | 4.1 | 9.0 |
| Week 20: ACR 20 responders | 22.4 | 63.0 |
| Week 20: ACR 50 responders | 10.2 | 37.0 |
| Week 20: ACR 70 responders | 2.0 | 11.0 |
| Week 24: ACR 20 responders | 18.4 | 58.0 |
| Week 24: ACR 50 responders | 10.2 | 34.0 |
| Week 24: ACR 70 responders | 2.0 | 14.0 |
ACR 20, ACR 50 and ACR 70 response is defined as at least 20%, 50%, and 70% improvement from baseline in swollen joint (66 joints) and tender joint (68 joints) counts and at least 20%, 50%, and 70% improvement from baseline in 3 of following 5 assessments: patient's assessment of pain (VAS: 0-100mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity on arthritis (VAS: 0-100mm; 0=excellent and 100=poor), physician's global assessment of disease activity (VAS; 0-100mm; 0=no arthritis activity and 100 = extremely active arthritis), patient's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas;derived HAQ-DI ranges from 0 indicating no difficulty, to 3 indicating inability to perform a task in that area) and serum C-Reactive Protein (CRP). As planned, results data was analyzed and reported for the specified arms for this outcome measure.
| percentage of participants | Placebo to Guselkumab (Week 24 to Week 56) | Guselkumab (Week 24 to Week 52) |
|---|---|---|
| Week 24: ACR 20 responders | 31.0 | 66.3 |
| Week 24: ACR 50 responders | 17.2 | 39.5 |
| Week 24: ACR 70 responders | 3.4 | 16.3 |
| Week 28: ACR 20 responders | 57.1 | 75.3 |
| Week 28: ACR 50 responders | 28.6 | 44.7 |
| Week 28: ACR 70 responders | 14.3 | 30.6 |
| Week 32: ACR 20 responders | 60.7 | 75.0 |
| Week 32: ACR 50 responders | 42.9 | 51.2 |
| Week 32: ACR 70 responders | 21.4 | 29.8 |
| Week 36: ACR 20 responders | 71.4 | 73.8 |
| Week 36: ACR 50 responders | 46.4 | 48.8 |
| Week 36: ACR 70 responders | 29.6 | 31.0 |
| Week 44: ACR 20 responders | 75.0 | 77.4 |
| Week 44: ACR 50 responders | 46.4 | 46.4 |
| Week 44: ACR 70 responders | 25.0 | 26.2 |
| Week 56: ACR 20 responders | 81.5 | 73.5 |
| Week 56: ACR 50 responders | 66.7 | 53.0 |
| Week 56: ACR 70 responders | 28.6 | 32.5 |
The 7 components of ACR response are: swollen joint counts (0-66), tender joint counts (0-68), patient's assessment of pain (PAIN) (VAS:0-100mm; 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (GDPT) on arthritis (VAS:0-100mm; 0=excellent and 100= poor), physician's global assessment of disease activity (GDEV) (VAS: 0-100mm; 0=no arthritis activity and 100 = extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (20-question instrument assessing 8 functional areas (total score of 0-24 with lower score indicating better functioning);derived HAQ-DI ranges from 0 indicating no difficulty, to 3 indicating inability to perform a task in that area) and serum CRP.
| percent change | Placebo | Guselkumab |
|---|---|---|
| Week 12: Swollen joints (0-66) | -29.41 (-50.0 to 0.0) | -64.50 (-93.8 to -30.0) |
| Week 12: Tender joints (0-68) | -13.33 (-46.7 to 15.4) | -45.80 (-78.0 to -25.0) |
| Week 12: PAIN (VAS, 0-100 mm) | 1.79 (-20.0 to 15.6) | -22.05 (-46.1 to -2.6) |
| Week 12: GDPT (VAS, 0-100 mm, arthritis) | -11.39 (-41.0 to 9.2) | -55.24 (-74.5 to -22.1) |
| Week 12: GDEV (VAS, 0-100 mm) | -11.39 (-41.0 to 9.2) | -55.24 (-74.5 to -22.1) |
| Week 12: HAQ-DI score (0-3) | 0.00 (-25.0 to 8.3) | -21.43 (-40.0 to -6.7) |
| Week 12: CRP | -3.95 (-41.3 to 51.2) | -42.95 (-69.8 to 10.7) |
| Week 24: Swollen joints (0-66) | -11.76 (-59.1 to 11.8) | -84.11 (-100.0 to -43.2) |
| Week 24: Tender joints (0-68) | -5.56 (-53.1 to 30.8) | -51.05 (-89.6 to -23.7) |
| Week 24: PAIN (VAS, 0-100 mm) | 2.38 (-20.9 to 32.8) | -32.93 (-70.7 to -7.6) |
| Week 24: GDPT (VAS, 0-100 mm, arthritis) | -2.22 (-26.8 to 26.1) | -35.53 (-68.2 to -7.2) |
| Week 24: GDEV (VAS, 0-100 mm) | -8.86 (-48.1 to 11.1) | -68.47 (-86.6 to -37.0) |
| Week 24: HAQ-DI score (0-3) | -10.00 (-27.3 to 12.5) | -28.57 (-52.9 to -8.3) |
| Week 24: CRP | 7.94 (-30.3 to 93.5) | -42.64 (-77.7 to 2.3) |
The 7 components of ACR response are: swollen joint counts (0-66), tender joint counts (0-68), patient's assessment of pain (PAIN) (VAS:0-100mm; 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (GDPT) on arthritis (VAS:0-100mm; 0=excellent and 100= poor), physician's global assessment of disease activity (GDEV) (VAS: 0-100mm; 0=no arthritis activity and 100 = extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (20-question instrument assessing 8 functional areas (total score of 0-24 with lower score indicating better functioning);derived HAQ-DI ranges from 0 indicating no difficulty, to 3 indicating inability to perform a task in that area) and serum CRP.
| percent change | Placebo to Guselkumab (Week 24 to Week 56) | Guselkumab (Week 24 to Week 52) |
|---|---|---|
| Week 24: Swollen joints (0-66) | -33.33 (-80.0 to -11.8) | -85.71 (-100.0 to -63.3) |
| Week 28: Swollen joints (0-66) | -69.05 (-83.3 to -32.7) | -93.75 (-100.0 to -60.9) |
| Week 32: Swollen joints (0-66) | -84.91 (-95.8 to -50.0) | -100.00 (-100.0 to -73.9) |
| Week 36: Swollen joints (0-66) | -79.14 (-100.0 to -57.7) | -93.93 (-100.0 to -66.7) |
| Week 44: Swollen joints (0-66) | -86.11 (-100.0 to -64.6) | -94.56 (-100.0 to -70.6) |
| Week 56: Swollen joints (0-66) | -100.00 (-100.0 to -63.6) | -100.00 (-100.0 to -75.0) |
| Week 24: Tender joints (0-68) | -50.00 (-74.5 to -14.9) | -72.00 (-90.0 to -45.8) |
| Week 28: Tender joints (0-68) | -65.99 (-83.3 to -17.0) | -74.36 (-91.3 to -50.0) |
| Week 32: Tender joints (0-68) | -71.76 (-86.1 to -27.7) | -79.66 (-92.3 to -50.0) |
| Week 36: Tender joints (0-68) | -81.67 (-91.2 to -27.1) | -73.32 (-94.6 to -50.5) |
| Week 44: Tender joints (0-68) | -86.06 (-93.5 to -50.0) | -77.22 (-97.0 to -49.0) |
| Week 56: Tender joints (0-68) | -80.00 (-93.8 to -51.2) | -77.27 (-100.0 to -58.8) |
| Week 24: PAIN (VAS, 0-100 mm) | -11.69 (-34.6 to 14.8) | -40.98 (-72.3 to -9.2) |
| Week 28: PAIN (VAS, 0-100 mm) | -23.52 (-59.7 to 4.4) | -49.40 (-80.9 to -14.1) |
| Week 32: PAIN (VAS, 0-100 mm) | -51.08 (-70.9 to -4.9) | -50.00 (-78.7 to -22.2) |
| Week 36: PAIN (VAS, 0-100 mm) | -61.13 (-79.6 to -11.5) | -55.83 (-83.3 to -21.4) |
| Week 44: PAIN (VAS, 0-100 mm) | -58.76 (-83.9 to -11.4) | -45.50 (-81.0 to -12.5) |
| Week 56: PAIN (VAS, 0-100 mm) | -71.99 (-85.0 to -31.5) | -52.44 (-85.7 to -13.7) |
| Week 24: GDPT (VAS, 0-100 mm, arthritis) | -17.74 (-35.1 to 5.7) | -41.98 (-70.4 to -8.9) |
| Week 28: GDPT (VAS, 0-100 mm, arthritis) | -40.73 (-66.5 to -5.7) | -52.17 (-76.9 to -18.8) |
| Week 32: GDPT (VAS, 0-100 mm, arthritis) | -48.62 (-75.4 to -14.0) | -56.83 (-78.2 to -24.0) |
| Week 36: GDPT (VAS, 0-100 mm, arthritis) | -52.17 (-81.0 to -29.1) | -52.09 (-81.9 to -15.5) |
| Week 44: GDPT (VAS, 0-100 mm, arthritis) | -49.53 (-80.1 to -11.4) | -47.21 (-82.6 to -13.6) |
| Week 56: GDPT (VAS, 0-100 mm, arthritis) | -68.12 (-87.1 to -31.8) | -55.32 (-84.0 to -11.8) |
| Week 24: GDEV (VAS, 0-100 mm) | -37.88 (-60.6 to -8.9) | -72.41 (-89.7 to -51.5) |
| Week 28: GDEV (VAS, 0-100 mm) | -66.07 (-86.6 to -48.6) | -80.26 (-92.2 to -55.9) |
| Week 32: GDEV (VAS, 0-100 mm) | -71.40 (-88.1 to -56.4) | -82.14 (-93.3 to -60.0) |
| Week 36: GDEV (VAS, 0-100 mm) | -81.82 (-89.2 to -65.9) | -79.75 (-93.0 to -57.1) |
| Week 44: GDEV (VAS, 0-100 mm) | -82.41 (-89.8 to -65.0) | -80.00 (-92.1 to -61.2) |
| Week 56: GDEV (VAS, 0-100 mm) | -86.36 (-94.9 to -74.4) | -83.93 (-93.0 to -54.1) |
| Week 24: HAQ-DI score (0-3) | -19.38 (-50.0 to 3.8) | -37.50 (-58.8 to -12.5) |
| Week 28: HAQ-DI score (0-3) | -31.25 (-80.0 to 0.0) | -41.05 (-75.0 to -10.0) |
| Week 32: HAQ-DI score (0-3) | -42.86 (-75.0 to -10.0) | -41.18 (-80.0 to -12.5) |
| Week 36: HAQ-DI score (0-3) | -50.00 (-81.3 to -12.5) | -37.50 (-80.0 to -12.5) |
| Week 44: HAQ-DI score (0-3) | -57.14 (-80.0 to -25.0) | -37.50 (-80.0 to -12.5) |
| Week 56: HAQ-DI score (0-3) | -54.55 (-83.3 to -38.5) | -39.23 (-80.4 to -11.8) |
| Week 24: CRP | 6.19 (-30.3 to 93.5) | -43.62 (-79.0 to 3.7) |
| Week 28: CRP | -35.63 (-52.7 to -1.6) | -52.70 (-79.6 to -1.7) |
| Week 32: CRP | -42.61 (-60.8 to -21.8) | -50.63 (-78.7 to -4.1) |
| Week 36: CRP | -38.90 (-70.0 to -13.3) | -53.22 (-81.4 to -6.0) |
| Week 44: CRP | -53.43 (-76.9 to -36.5) | -53.36 (-75.7 to -10.3) |
| Week 56: CRP | -51.26 (-81.5 to -37.8) | -54.91 (-79.3 to 25.7) |
Change from baseline in HAQ-DI score is a measure of the change in the physical function, where a negative change reflects an improvement and a positive change reflects worsening of physical function. HAQ-DI is a 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0 indicating no difficulty, to 3 indicating inability to perform a task in that area (that is, lower scores are indicative of better functioning). The total HAQ-DI score ranges from 0-24 with lower score indicating better functioning.
| units on a scale | Placebo | Guselkumab |
|---|---|---|
| Week 4 | -0.02 ± 0.329 | -0.17 ± 0.322 |
| Week 8 | -0.07 ± 0.440 | -0.32 ± 0.442 |
| Week 12 | -0.05 ± 0.450 | -0.33 ± 0.390 |
| Week 16 | -0.05 ± 0.428 | -0.38 ± 0.397 |
| Week 20 | -0.08 ± 0.479 | -0.41 ± 0.453 |
| Week 24 | -0.06 ± 0.530 | -0.42 ± 0.512 |
Change from baseline in HAQ-DI score is a measure of the change in the physical function, where a negative change reflects an improvement and a positive change reflects worsening of physical function. HAQ-DI is a 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area (that is, lower scores are indicative of better functioning). The total HAQ-DI score ranges from 0-24 with lower score indicating better functioning.
| units on a scale | Placebo to Guselkumab (Week 24 to Week 56) | Guselkumab (Week 24 to Week 52) |
|---|---|---|
| Week 24 | -0.19 ± 0.581 | -0.46 ± 0.530 |
| Week 28 | -0.40 ± 0.646 | -0.51 ± 0.571 |
| Week 32 | -0.50 ± 0.624 | -0.56 ± 0.595 |
| Week 36 | -0.59 ± 0.650 | -0.53 ± 0.618 |
| Week 44 | -0.63 ± 0.612 | -0.54 ± 0.598 |
| Week 56 | -0.67 ± 0.558 | -0.55 ± 0.621 |
HAQ-DI response was defined as \>= 0.3 improvement from baseline in HAQ-DI score. HAQ-DI is a 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0 indicating no difficulty, to 3 indicating inability to perform a task in that area (that is, lower scores are indicative of better functioning). The total HAQ-DI score ranges from 0-24 with lower score indicating better functioning.
| percentage of participants | Placebo | Guselkumab |
|---|---|---|
| Week 4 | 12.2 | 29.0 |
| Week 8 | 26.5 | 43.0 |
| Week 12 | 22.4 | 47.0 |
| Week 16 | 20.4 | 50.0 |
| Week 20 | 22.4 | 48.0 |
| Week 24 | 28.6 | 51.0 |
HAQ-DI response was defined as \>= 0.3 improvement from baseline in HAQ-DI score. HAQ-DI is a 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0 indicating no difficulty, to 3 indicating inability to perform a task in that area (that is, lower scores are indicative of better functioning). The total HAQ-DI score ranges from 0-24 with lower score indicating better functioning. As planned, results data was analyzed and reported for the specified arms for this outcome measure.
| percentage of participants | Placebo to Guselkumab (Week 24 to Week 56) | Guselkumab (Week 24 to Week 52) |
|---|---|---|
| Week 24 | 44.8 | 55.8 |
| Week 28 | 53.6 | 60.0 |
| Week 32 | 57.1 | 56.0 |
| Week 36 | 64.3 | 59.5 |
| Week 44 | 71.4 | 61.9 |
| Week 56 | 75.0 | 59.0 |
Dactylitis is characterized by swelling of the entire finger or toe. The severity of dactylitis is scored on a scale of 0-3, where 0, 1, 2, 3 indicates none, mild, moderate, severe, respectively in each digit of the hands and feet. The range of total dactylitis scores for a participant is 0-60. Higher score indicates more severe dactylitis.
| percent change | Placebo | Guselkumab |
|---|---|---|
| Week 4 | -33.33 (-50.0 to 0.0) | -32.46 (-100.0 to 0.0) |
| Week 8 | -50.00 (-75.00 to 0.0) | -75.00 (-100.0 to -10.0) |
| Week 16 | -50.00 (-80.0 to 0.0) | -100.00 (-100.0 to -33.3) |
| Week 24 | -33.33 (-66.7 to 0.0) | -100.00 (-100.00 to -50.0) |
Dactylitis was characterized by swelling of the entire finger or toe. The severity of dactylitis is scored on a scale of 0-3, where 0, 1, 2, 3 indicates none, mild, moderate, severe, respectively in each digit of the hands and feet. The range of total dactylitis scores for a participant is 0-60. Higher score indicates more severe dactylitis. As planned, results data was analyzed and reported for the specified arms for this outcome measure.
| percent change | Placebo to Guselkumab (Week 24 to Week 56) | Guselkumab (Week 24 to Week 52) |
|---|---|---|
| Week 24 | -45.00 (-70.8 to 0.0) | -100.00 (-100.0 to -80.0) |
| Week 28 | -70.83 (-100.0 to -22.5) | -100.00 (-100.00 to -66.7) |
| Week 32 | -100.00 (-100.00 to -79.2) | -100.00 (-100.00 to -70.0) |
| Week 44 | -100.00 (-100.00 to -100.00) | -100.00 (-100.00 to -100.00) |
| Week 56 | -100.00 (-100.00 to -100.00) | -100.00 (-100.00 to -95.0) |
Dactylitis is characterized by swelling of the entire finger or toe. The severity of dactylitis is scored on a scale of 0-3, where 0, 1, 2, 3 indicates none, mild, moderate, severe, respectively in each digit of the hands and feet. The range of total dactylitis scores for a participant is 0-60. Participants with dactylitis had dactylitis score \>0. Higher score indicates more severe dactylitis.
| percentage of participants | Placebo | Guselkumab |
|---|---|---|
| Week 4 | 91.3 | 72.4 |
| Week 8 | 69.6 | 56.9 |
| Week 16 | 78.3 | 48.3 |
| Week 24 | 82.6 | 44.8 |
Dactylitis was characterized by swelling of the entire finger or toe. The severity of dactylitis is scored on a scale of 0-3, where 0, 1, 2, 3 indicates none, mild, moderate, severe, respectively in each digit of the hands and feet. The range of total dactylitis scores for a participant is 0-60. Higher score indicates greater degree of tenderness.
| percentage of participants | Placebo to Guselkumab (Week 24 to Week 56) | Guselkumab (Week 24 to Week 52) |
|---|---|---|
| Week 24 | 81.3 | 40.0 |
| Week 28 | 62.5 | 38.8 |
| Week 32 | 31.3 | 36.7 |
| Week 44 | 12.5 | 20.4 |
| Week 56 | 6.3 | 25.0 |
Enthesitis was assessed using the Leeds Enthesitis Index (LEI). The LEI was developed to assess enthesitis in participants with psoriatic arthritis (PsA), and evaluates the presence (score of 1) or absence of pain (score of 0) by applying local pressure to Lateral elbow epicondyle, left and right, Medial femoral condyle, left and right, and Achilles tendon insertion, left and right. LEI scores ranging from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness).
| percent change | Placebo | Guselkumab |
|---|---|---|
| Week 4 | 0.00 (-50.0 to 0.0) | -18.33 (-79.2 to 0.0) |
| Week 8 | 0.00 (-60.0 to 0.0) | -58.33 (-100.0 to 0.0) |
| Week 16 | 0.00 (-50.0 to 0.00) | -50.04 (-100.0 to 0.00) |
| Week 24 | -33.33 (-100.00 to 0.0) | -100.00 (-100.00 to 0.0) |
Enthesitis will be assessed using the Leeds Enthesitis Index (LEI). The LEI was developed to assess enthesitis in participants with PsA, and evaluates the presence (score of 1) or absence of pain (score of 0) by applying local pressure to Lateral elbow epicondyle, left and right, Medial femoral condyle, left and right, and Achilles tendon insertion, left and right. LEI scores ranging from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness).
| percent change | Placebo to Guselkumab (Week 24 to Week 56) | Guselkumab (Week 24 to Week 52) |
|---|---|---|
| Week 24 | -50.00 (-100.0 to 0.0) | -100.00 (-100.0 to -50.0) |
| Week 28 | -60.00 (-100.0 to -40.0) | -100.00 (-100.0 to -50.0) |
| Week 32 | -100.00 (-100.0 to -60.0) | -100.00 (-100.0 to -66.7) |
| Week 44 | -100.00 (-100.0 to -60.0) | -100.00 (-100.0 to -50.0) |
| Week 56 | -100.00 (-100.0 to -35.0) | -100.00 (-100.0 to -50.0) |
Enthesitis was assessed using the Leeds Enthesitis Index (LEI). The LEI was developed to assess enthesitis in participants with PsA, and evaluates the presence (score of 1) or absence of pain (score of 0) by applying local pressure to Lateral elbow epicondyle, left and right, Medial femoral condyle, left and right, and Achilles tendon insertion, left and right. Participants with enthesitis had LEI score \>0. LEI scores ranging from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness).
| percentage of Participants | Placebo | Guselkumab |
|---|---|---|
| Week 4 | 87.1 | 76.3 |
| Week 8 | 87.1 | 59.2 |
| Week 16 | 83.9 | 53.9 |
| Week 24 | 71.0 | 43.4 |
Enthesitis will be assessed using the Leeds Enthesitis Index (LEI). The LEI was developed to assess enthesitis in participants with PsA, and evaluates the presence (score of 1) or absence of pain (score of 0) by applying local pressure to Lateral elbow epicondyle, left and right, Medial femoral condyle, left and right, and Achilles tendon insertion, left and right. Participants with enthesitis had LEI score \>0. LEI scores ranging from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness).
| percentage of participants | Placebo to Guselkumab (Week 24 to Week 56) | Guselkumab (Week 24 to Week 52) |
|---|---|---|
| Week 24 | 66.7 | 38.8 |
| Week 28 | 64.7 | 44.8 |
| Week 32 | 35.3 | 31.8 |
| Week 44 | 47.1 | 37.9 |
| Week 56 | 37.5 | 29.2 |
Change from baseline in PASDAS score measures the change in disease activity where a negative value indicates an improvement and a positive value indicates worsening of PsA disease activity. PASDAS is a PsA disease activity score that assesses 4 domains (joints, entheses, dactylitis and quality of life) of PsA. PASDAS is a derived score combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, on a 100-unit VAS), Physician's Global Assessment of Disease Activity (on a 100-unit VAS), swollen joint count (66 joints), tender joint count (68 joints), CRP (mg/L), enthesitis based on LEI (scaled to a 0-6 range), dactylitis count (scoring each digit from 0-3 and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score of the SF-36 health survey. The total score range is 0-10 and the cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.
| units on a scale | Placebo | Guselkumab |
|---|---|---|
| Week 16 | -0.45 ± 1.099 | -2.24 ± 1.458 |
| Week 24 | -0.49 ± 1.333 | -2.50 ± 1.587 |
Change from baseline in PASDAS score measures the change in disease activity where a negative value indicates an improvement and a positive value indicates worsening of PsA disease activity. PASDAS is a PsA disease activity score that assesses 4 domains (joints, entheses, dactylitis and quality of life) of PsA. PASDAS is a derived score combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, on a 100-unit VAS), Physician's Global Assessment of Disease Activity (on a 100-unit VAS), swollen joint count (66 joints), tender joint count (68 joints), CRP (mg/L), enthesitis based on LEI (scaled to a 0-6 range), dactylitis count (scoring each digit from 0-3 and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score of the SF-36 health survey. The total score range is 0-10 and the cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.
| units on a scale | Placebo to Guselkumab (Week 24 to Week 56) | Guselkumab (Week 24 to Week 52) |
|---|---|---|
| Week 24 | -1.05 ± 1.440 | -2.80 ± 1.454 |
| Week 44 | -3.17 ± 1.524 | -3.15 ± 1.570 |
Change from baseline in GRACE index score measures the change in disease activity, where a negative change indicates an improvement and a positive change indicates a worsening of PsA disease activity. GRACE index was converted from Arithmetic Mean of the Desirability Function (AMDF). AMDF is calculated by transforming all variables using predefined algorithms and expressing the total score as a mean with a score range of 0 - 1, where 1 indicates a better state than 0. GRACE Index = (1 - AMDF)\*10, where GRACE index has a range of 0-10, with higher scores indicate more active disease. As planned, results data was analyzed and reported for the specified arms for this outcome measure.
| units on a scale | Placebo | Guselkumab |
|---|---|---|
| Week 16 | -0.29 ± 1.174 | -2.49 ± 1.614 |
| Week 24 | -0.35 ± 1.394 | -2.73 ± 1.756 |
Change from baseline in GRACE index score measures the change in disease activity, where a negative change indicates an improvement and a positive change indicates a worsening of PsA disease activity. GRACE index was converted from Arithmetic Mean of the Desirability Function (AMDF). AMDF is calculated by transforming all variables using predefined algorithms and expressing the total score as a mean with a score range of 0 - 1, where 1 indicates a better state than 0. GRACE Index = (1 - AMDF)\*10, where GRACE index has a range of 0-10, with higher scores indicate more active disease.
| units on a scale | Placebo to Guselkumab (Week 24 to Week 56) | Guselkumab (Week 24 to Week 52) |
|---|---|---|
| Week 24 | -0.91 ± 1.498 | -2.96 ± 1.717 |
| Week 44 | -3.21 ± 1.698 | -3.26 ± 1.856 |
The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity.
| units on a scale | Placebo | Guselkumab |
|---|---|---|
| Week 16 | -0.5 ± 1.88 | -3.1 ± 2.48 |
| Week 24 | -0.8 ± 2.16 | -3.9 ± 2.72 |
The mCPDAI assessed 4 domains (joints, skin, entheses, and dactylitis). The mCPDAI scores were calculated using the following assessments: joints (66 swollen and 68 tender joint counts), HAQ-DI score, PASI, dactylitis, and enthesitis. Within each domain a score (range 0-3) was assigned, where 0= Not involved, 1= Mild, 2= Moderate and 3= Severe. The scores for each domain were then added together to give a final score range of 0 to 12. A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity.
| units on a scale | Placebo to Guselkumab (CO) at Week 24 | Guselkumab (Week 24 to Week 52) |
|---|---|---|
| Week 24 | -1.4 ± 2.27 | -4.3 ± 2.69 |
| Week 44 | -4.2 ± 2.88 | -4.8 ± 2.55 |
Change from baseline in DAPSA measures the change in disease activity, where a negative change indicates an improvement and a positive change indicates worsening of disease activity. DAPSA score is a the sum of swollen joint count (66 joints), tender joint count (68 joints), CRP (mg/dL), Patient's Assessment of Pain (on a 10-unit VAS;0=no pain, 10=worst possible pain), and Patient's Global Assessment of Disease Activity (arthritis, on a 10-unit VAS; 0 to 100 centimeter \[cm\] VAS, 0=excellent and 10=poor). Cut-off values for disease activity: 0-4 remission; 5-14 low; 15-28 moderate; \>28 high.
| units on a scale | Placebo | Guselkumab |
|---|---|---|
| Week 4 | -5.62 ± 13.030 | -10.03 ± 11.207 |
| Week 8 | -8.25 ± 15.158 | -16.65 ± 15.948 |
| Week 12 | -6.84 ± 16.334 | -18.84 ± 16.266 |
| Week 16 | -4.98 ± 16.045 | -21.26 ± 17.811 |
| Week 20 | -4.70 ± 17.408 | -22.56 ± 19.918 |
| Week 24 | -4.97 ± 20.114 | -23.08 ± 20.206 |
Change from baseline in DAPSA measures the change in disease activity, where a negative change indicates an improvement and a positive change indicates worsening of disease activity. DAPSA score is a the sum of swollen joint count (66 joints), tender joint count (68 joints), CRP (mg/dL), Patient's Assessment of Pain (on a 10-unit VAS;0=no pain, 10=worst possible pain), and Patient's Global Assessment of Disease Activity (arthritis, on a 10-unit VAS; 0 to 10cm VAS, 0=excellent and 10=poor). Cut-off values for disease activity: 0-4 remission; 5-14 low; 15-28 moderate; \>28 high.
| units on a scale | Placebo to Guselkumab (Week 24 to Week 56) | Guselkumab (Week 24 to Week 52) |
|---|---|---|
| Week 24 | -12.99 ± 22.328 | -26.93 ± 18.238 |
| Week 28 | -20.85 ± 21.434 | -29.71 ± 18.911 |
| Week 32 | -26.12 ± 21.309 | -30.59 ± 19.720 |
| Week 36 | -27.37 ± 22.480 | -30.43 ± 18.114 |
| Week 44 | -29.54 ± 20.785 | -30.55 ± 18.188 |
| Week 56 | -31.98 ± 20.359 | -32.02 ± 18.328 |
MDA defines a satisfactory state of disease activity that includes 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity on arthritis and psoriasis, physical function and enthesitis). Participants were classified as achieving MDA if they fulfilled 5 of 7 outcome measures: tender joint count \<=1; swollen joint count \<=1; PASI \<=1; patient pain VAS score of \<=15 mm; patient global disease activity on arthritis and psoriasis; VAS score of \<=20 mm; Health Assessment Questionnaire score \<=0.5; and tender entheseal points \<=1.
| percentage of participants | Placebo | Guselkumab |
|---|---|---|
| Week 16 | 0 | 18.0 |
| Week 24 | 2.0 | 23.0 |
MDA defines a satisfactory state of disease activity that includes 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity on arthritis and psoriasis, physical function and enthesitis). Participants were classified as achieving MDA if they fulfilled 5 of 7 outcome measures: tender joint count \<=1; swollen joint count \<=1; PASI \<=1; patient pain VAS score of \<=15 mm; patient global disease activity on arthritis and psoriasis; VAS score of \<=20 mm; Health Assessment Questionnaire score \<=0.5; and tender entheseal points \<=1.
| percentage of participants | Placebo to Guselkumab (Week 24 to Week 56) | Guselkumab (Week 24 to Week 52) |
|---|---|---|
| Week 24 | 3.4 | 26.7 |
| Week 44 | 28.6 | 34.5 |
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS and MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms as presented in this outcome measure. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
| units on a scale | Placebo | Guselkumab |
|---|---|---|
| Week 16: PCS | -0.44 ± 5.025 | 5.86 ± 7.315 |
| Week 24: PCS | 0.46 ± 6.513 | 6.59 ± 7.465 |
| Week 16: MCS | 1.14 ± 7.075 | 4.80 ± 8.952 |
| Week 24: MCS | 0.42 ± 6.737 | 4.95 ± 9.064 |
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms as presented in this outcome measure. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
| units on a scale | Placebo to Guselkumab (Week 24 to Week 56) | Guselkumab (Week 24 to Week 52) |
|---|---|---|
| Week 24: PCS | 2.13 ± 7.365 | 7.40 ± 7.448 |
| Week 44: PCS | 8.02 ± 8.647 | 8.34 ± 8.783 |
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms as presented in this outcome measure. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
| units on a scale | Placebo to Guselkumab (Week 24 to Week 56) | Guselkumab (Week 24 to Week 52) |
|---|---|---|
| Week 24: MCS | 0.51 ± 6.770 | 5.45 ± 9.081 |
| Week 44: MCS | 5.53 ± 9.013 | 4.56 ± 9.548 |
SF-36 evaluates 8 individual subscales (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health). Each 8 scales scored from 0 to 100 with higher scores= better health. The scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher scores indicate better health. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
| T-score | Placebo | Guselkumab |
|---|---|---|
| Week 16: Physical functioning | -0.31 ± 6.657 | 6.30 ± 7.255 |
| Week 24: Physical functioning | -0.04 ± 8.227 | 6.93 ± 8.009 |
| Week 16: Role-physical | -0.23 ± 5.674 | 4.22 ± 7.146 |
| Week 24: Role-physical | -0.09 ± 6.813 | 4.69 ± 7.961 |
| Week 16: Bodily pain | 0.21 ± 5.675 | 6.56 ± 7.832 |
| Week 24: Bodily pain | 0.81 ± 6.445 | 7.56 ± 8.288 |
| Week 16: General health | 0.74 ± 5.857 | 6.19 ± 7.964 |
| Week 24: General health | 1.49 ± 7.274 | 6.48 ± 7.676 |
| Week 16: Vitality | 0.73 ± 7.779 | 5.85 ± 8.138 |
| Week 24: Vitality | 1.46 ± 7.254 | 6.39 ± 8.861 |
| Week 16: Social functioning | -0.82 ± 8.272 | 5.87 ± 9.346 |
| Week 24: Social functioning | -0.82 ± 7.613 | 6.22 ± 10.426 |
| Week 16: Role-emotional | 1.14 ± 8.774 | 4.77 ± 9.643 |
| Week 24: Role-emotional | 0.64 ± 8.754 | 4.67 ± 9.393 |
| Week 16: Mental health | 1.28 ± 7.007 | 5.10 ± 8.683 |
| Week 24: Mental health | 0.21 ± 7.020 | 5.68 ± 8.877 |
SF-36 evaluates 8 individual subscales (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health). Each 8 scales scored from 0 to 100 with higher scores= better health. The scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher scores indicate better health. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
| T-score | Placebo to Guselkumab (Week 24 to Week 56) | Guselkumab (Week 24 to Week 52) |
|---|---|---|
| Week 24: Physical functioning | 1.09 ± 8.953 | 7.54 ± 8.228 |
| Week 44: Physical functioning | 8.41 ± 9.969 | 8.50 ± 8.633 |
| Week 24: Role-physical | 1.92 ± 7.119 | 5.74 ± 7.480 |
| Week 44: Role-physical | 6.82 ± 9.198 | 6.66 ± 7.664 |
| Week 24: Bodily pain | 2.88 ± 6.856 | 8.39 ± 8.332 |
| Week 44: Bodily pain | 9.42 ± 8.914 | 8.95 ± 9.952 |
| Week 24: General health | 1.94 ± 8.185 | 7.05 ± 7.657 |
| Week 44: General health | 6.25 ± 8.998 | 6.74 ± 8.496 |
| Week 24: Vitality | 1.49 ± 7.387 | 7.39 ± 8.727 |
| Week 44: Vitality | 7.53 ± 10.802 | 7.11 ± 9.891 |
| Week 24: Social functioning | -0.18 ± 7.776 | 6.41 ± 10.919 |
| Week 44: Social functioning | 6.09 ± 10.151 | 5.73 ± 10.357 |
| Week 24: Role-emotional | 2.11 ± 7.891 | 5.30 ± 9.013 |
| Week 44: Role-emotional | 5.47 ± 9.160 | 5.68 ± 9.635 |
| Week 24: Mental health | 0.19 ± 7.465 | 6.30 ± 8.994 |
| Week 44: Mental health | 7.29 ± 9.952 | 5.42 ± 8.978 |
RAPID3 is a multi-dimensional health assessment questionnaire that was designed for use in routine clinical care. Three core data set for function, pain, and patient global estimate of disease activity were recorded. Each was scored 0-10 and the score ranges from 0 to 30 with higher scores indicating worse condition. A negative change from baseline indicates improvement in condition.
| units on a scale | Placebo | Guselkumab |
|---|---|---|
| Week 16 | -0.19 ± 4.405 | -5.41 ± 5.307 |
| Week 24 | -0.57 ± 5.123 | -5.81 ± 5.968 |
RAPID3 is a multi-dimensional health assessment questionnaire that was designed for use in routine clinical care. Three core data set for function, pain, and patient global estimate of disease activity were recorded. Each was scored 0-10 and the score ranges from 0 to 30 with higher scores indicating worse condition. A negative change from baseline indicates improvement in condition.
| units on a scale | Placebo to Guselkumab (CO) at Week 24 | Guselkumab |
|---|---|---|
| Week 24 | -2.28 ± 5.244 | -6.36 ± 6.205 |
| Week 44 | -7.60 ± 6.588 | -7.48 ± 6.310 |
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. PASI 50, 75, 90, and 100 responses were defined as at least a 50%, 75%, 90%, and 100% reduction in PASI relative to Baseline respectively. As planned, results data was analyzed and reported for the specified arms for this outcome measure.
| percentage of participants | Placebo | Guselkumab |
|---|---|---|
| Week 16: PASI 50 responders | 27.1 | 81.6 |
| Week 16: PASI 75 responders | 8.3 | 71.4 |
| Week 16: PASI 90 responders | 6.3 | 53.1 |
| Week 16: PASI 100 responders | 6.3 | 31.6 |
| Week 24: PASI 50 responders | 29.2 | 86.7 |
| Week 24: PASI 75 responders | 12.5 | 78.6 |
| Week 24: PASI 90 responders | 6.3 | 66.3 |
| Week 24: PASI 100 responders | 6.3 | 39.8 |
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. PASI 50, 75, 90, and 100 responses were defined as at least a 50%, 75%, 90%, and 100% reduction in PASI relative to Baseline respectively.
| percentage of participants | Placebo to Guselkumab (Week 24 to Week 56) | Guselkumab (Week 24 to Week 52) |
|---|---|---|
| Week 24: PASI 50 responders | 37.9 | 89.5 |
| Week 24: PASI 75 responders | 20.7 | 82.6 |
| Week 24: PASI 90 responders | 10.3 | 70.9 |
| Week 24: PASI 100 responders | 10.3 | 44.2 |
| Week 28: PASI 50 responders | 60.7 | 95.2 |
| Week 28: PASI 75 responders | 35.7 | 84.5 |
| Week 28: PASI 90 responders | 25.0 | 72.6 |
| Week 28: PASI 100 responders | 17.9 | 53.6 |
| Week 32: PASI 50 responders | 78.6 | 92.8 |
| Week 32: PASI 75 responders | 67.9 | 86.7 |
| Week 32: PASI 90 responders | 50.0 | 80.7 |
| Week 32: PASI 100 responders | 35.7 | 62.7 |
| Week 44: PASI 50 responders | 89.3 | 94.0 |
| Week 44: PASI 75 responders | 82.1 | 90.4 |
| Week 44: PASI 90 responders | 75.0 | 81.9 |
| Week 44: PASI 100 responders | 67.9 | 63.9 |
| Week 56: PASI 50 responders | 96.3 | 92.7 |
| Week 56: PASI 75 responders | 81.5 | 85.4 |
| Week 56: PASI 90 responders | 74.1 | 78.0 |
| Week 56: PASI 100 responders | 55.6 | 57.3 |
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A negative percent change from baseline indicates the percent improvement from baseline in the severity of psoriatic lesions. As planned, results data was analyzed and reported for the specified arms for this outcome measure.
| percent change | Placebo | Guselkumab |
|---|---|---|
| Week 4 | 0.00 (-16.0 to 17.0) | -41.49 (-64.7 to -12.2) |
| Week 8 | 1.58 (-20.2 to 24.9) | -66.67 (-93.6 to -41.9) |
| Week 16 | -1.10 (-50.0 to 35.9) | -90.55 (-100.0 to -65.6) |
| Week 24 | -7.89 (-54.2 to 34.0) | -96.21 (-100.0 to -82.6) |
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A negative percent change from baseline indicates the percent improvement from baseline in the severity of psoriatic lesions.
| percent change | Placebo to Guselkumab (Week 24 to Week 56) | Guselkumab (Week 24 to Week 52) |
|---|---|---|
| Week 24 | -34.26 (-72.9 to 26.9) | -97.85 (-100.0 to -87.2) |
| Week 28 | -57.69 (-94.3 to -39.4) | -100.00 (-100.0 to -88.2) |
| Week 32 | -90.61 (-100.0 to -62.5) | -100.00 (-100.0 to -94.0) |
| Week 44 | -100.00 (-100.0 to -91.0) | -100.00 (-100.0 to -95.4) |
| Week 56 | -100.00 (-100.0 to -91.0) | -100.00 (-100.0 to -91.4) |
Collected over Up to Week 56. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Week 0 to Week 24) | 0/49 (0%) | 1/49 (2%) | 7/49 (14.3%) |
| Placebo to Guselkumab (Week 24 to Week 56) | 0/29 (0%) | 0/29 (0%) | 3/29 (10.3%) |
| Guselkumab (Week 0 to Week 56) | 0/100 (0%) | 6/100 (6%) | 24/100 (24%) |
| Placebo to Ustekinumab (EE: Week 16 to Week 56) | 0/17 (0%) | 0/17 (0%) | 8/17 (47.1%) |
| Guselkumab to Ustekinumab (EE:Week 16 to Week 56) | 0/10 (0%) | 0/10 (0%) | 3/10 (30%) |
| Event | Placebo (Week 0 to Week 24) | Placebo to Guselkumab (Week 24 to Week 56) | Guselkumab (Week 0 to Week 56) | Placebo to Ustekinumab (EE: Week 16 to Week 56) | Guselkumab to Ustekinumab (EE:Week 16 to Week 56) |
|---|---|---|---|---|---|
| Joint InjuryInjury, poisoning and procedural complications | 1/49 | 0/29 | 0/100 | 0/17 | 0/10 |
| Myocardial InfarctionCardiac disorders | 0/49 | 0/29 | 1/100 | 0/17 | 0/10 |
| Pupils UnequalEye disorders | 0/49 | 0/29 | 1/100 | 0/17 | 0/10 |
| Ulcerative KeratitisEye disorders | 0/49 | 0/29 | 1/100 | 0/17 | 0/10 |
| PneumoniaInfections and infestations | 0/49 | 0/29 | 1/100 | 0/17 | 0/10 |
| Radius FractureInjury, poisoning and procedural complications | 0/49 | 0/29 | 1/100 | 0/17 | 0/10 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/49 | 0/29 | 1/100 | 0/17 | 0/10 |
| Event | Placebo (Week 0 to Week 24) | Placebo to Guselkumab (Week 24 to Week 56) | Guselkumab (Week 0 to Week 56) | Placebo to Ustekinumab (EE: Week 16 to Week 56) | Guselkumab to Ustekinumab (EE:Week 16 to Week 56) |
|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 5/49 | 0/29 | 10/100 | 2/17 | 0/10 |
| Aspartate Aminotransferase IncreasedInvestigations | 0/49 | 2/29 | 3/100 | 0/17 | 1/10 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/49 | 0/29 | 0/100 | 0/17 | 1/10 |
| Oropharyngeal PainRespiratory, thoracic and mediastinal disorders | 0/49 | 0/29 | 0/100 | 0/17 | 1/10 |
| Alanine Aminotransferase IncreasedInvestigations | 1/49 | 2/29 | 4/100 | 0/17 | 0/10 |
| BronchitisInfections and infestations | 1/49 | 0/29 | 2/100 | 1/17 | 0/10 |
| CystitisInfections and infestations | 0/49 | 0/29 | 0/100 | 1/17 | 0/10 |
| Urinary Tract InfectionInfections and infestations | 0/49 | 0/29 | 2/100 | 1/17 | 0/10 |
| Weight IncreasedInvestigations | 1/49 | 0/29 | 0/100 | 1/17 | 0/10 |
| HeadacheNervous system disorders | 0/49 | 0/29 | 0/100 | 1/17 | 0/10 |
| Age, Continuous(years) | Placebo | Guselkumab | Total |
|---|---|---|---|
| Mean | 44.2 ± 12.43 | 47.4 ± 12.83 | 46.3 ± 12.75 |
| Sex: Female, Male(Participants) | Placebo | Guselkumab | Total |
|---|---|---|---|
| Female | 25 | 48 | 73 |
| Male | 24 | 52 | 76 |
| Region of Enrollment(Participants) | Placebo | Guselkumab | Total |
|---|---|---|---|
| Canada | 2 | 4 | 6 |
| Germany | 2 | 2 | 4 |
| Spain | 3 | 6 | 9 |
| Poland | 12 | 13 | 25 |
| Romania | 1 | 4 | 5 |
| Russia | 25 | 64 | 89 |
| United States | 4 | 7 | 11 |
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Janssen Research & Development, LLC